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The neonatal Fc receptor (FcRn), is a widely 
expressed Major Histocompatibilty Complex class 
I-like receptor that binds at acidic pH endogenous 
IgG and albumin and protects them from lysoso-
mal degradation by transporting them back to the 
cell surface to re-enter the circulation (Figure 
1A).1–4 The protective recycling role of FcRn 
extends the life span of endogenous serum IgG 
and albumin and ensures their abundance among 
all plasma proteins. Although this concept dates 
back to more than 50 years ago,5 it is now gaining 
major attention. Stimulated by the contribution of 
Su et al.6 in this issue of Therapeutic Advances in 
Neurological Disorders, this timely mini-review 
intends to highlight the role of FcRn in IgG home-
ostasis, the influence of FcRn genotypes on the 
efficacy of IVIg and monoclonal antibodies in 
neurological diseases, and the emerging role of the 
new neuro-immunotherapeutics that inhibit the 
capacity of FcRn to affect IgG autoantibodies.
The FcRn-mediated recycling of IgG is, based on 
mice studies, about 42% greater than the rate of IgG 
production,7 highlighting a remarkable economy of 
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Abstract: The neonatal Fc receptor (FcRn) binds endogenous IgG and protects it from lysosomal 
degradation by transporting it back to the cell surface to re-enter the circulation, extending the 
serum IgG life span. FcRn plays a role in the function of IVIg because the supraphysiological 
IgG levels derived from IVIg administrations saturate the FcRn allowing the endogenous IgG 
to be degraded, instead of being recycled, resulting in high levels of infused IgG ensuring IVIg 
efficiency. New data in myasthenia gravis patients suggest that the that the Variable Number of 
Tandem 3/2 (VNTR3/2) polymorphisms in FCGRT, the gene that encodes FcRn, may affect the 
duration of infused IgG in the circulation and IVIg effectiveness. This review addresses these 
implications in the context of whether the FCGRT genotype, by affecting the half-life of IVIg, 
may also play a role in up to 30% of patients with autoimmune neurological diseases, such as 
Guillain–Barré syndrome, CIDP or Multifocal Motor Neuropathy, who did not respond to IVIg in 
controlled trials. The concern is of practical significance because in such patient subsets super-
high IVIg doses may be needed to achieve high IgG levels and ensure efficacy. Whether FCGRT 
polymorphisms affect the efficacy of other therapeutic monoclonal antibodies by influencing 
their distribution clearance and pharmacokinetics, explaining their variable effectiveness, is also 
addressed. Finally, the very promising effect of monoclonal antibodies that inhibit FcRn, such 
as efgartigimod, rozanolixizumab and nipocalimab, in treating antibody-mediated neurological 
diseases is discussed along with their efficacy in the IgG4 subclass of pathogenic antibodies and 
their role in the blood–brain barrier endothelium, that abundantly expresses FcRn.
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nature to prolong the half-life of IgG and maintain a 
high IgG steady-state level in the circulation. This 
process is facilitated by the diverse expression of 
FcRn in several tissues throughout the body, includ-
ing epithelia, endothelia, hematopoietic cells and 
antigen-presenting cells, like dendritic cells and 
macrophages, important for T-cell-mediated immu-
nity.1–3 While in antibody deficiency syndromes the 
role of FcRn is protective to ensure a higher level of 
circulating IgG, in antibody-mediated diseases FcRn 
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Figure 1. Mechanism of action of the neonatal Fc receptor (FcRn) in protecting IgG from degradation (A) and 
enhancement of IgG catabolism by FcRn inhibitors (B). (A) When IgG molecules are ingested by pinocytosis, the 
pinocytic vesicles fuse with endosomes, which during their maturation become increasingly acidic, allowing 
binding of IgG with FcRn (shown in blue) sorting out what is not bound. The IgGs bound to FcRn are then retained 
and recycled to the cell surface where they are released to the circulation by exocytosis. The excess unbound 
IgGs enter the lysosomes for degradation. (B) FcRn inhibitors are monoclonal antibodies (projected in dark red 
cubes) engineered to increase binding to FcRn at neutral and acidic pH. When this happens, the ingested IgGs 
cannot bind to FcRn and remain unbound entering the lysosomes where they are degraded. The process results 
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may theoretically prolong the life even of pathologi-
cal autoantibodies. Targeting FcRn, therefore, either 
by reducing its availability, inhibiting its function or 
flooding the system with IgG as done with IVIg infu-
sions (where 1 g/kg of IVIg is equivalent to the total 
body IgG),2 offers novel therapeutic opportunities in 
autoimmune neurological diseases.
FcRn is encoded by FCGRT, a 14 kb gene located 
on the long arm of chromosome 19.8 Five differ-
ent alleles with a variable number of tandem 
repeat (VNTR) polymorphisms in the FCGRT 
gene, from VNTR1 to VNTR5, result in different 
expression levels of FcRn mRNA and protein lev-
els.8,9 VNTR3, the most common allele, is associ-
ated with an increase in promoter activity which 
in turn increases FcRn level in homozygous 
VNTR3/3 individuals, compared to the VNTR2 
allele or heterozygous VNTR3/2 individuals. On 
this basis, it has been argued that polymorphisms 
in the FCGRT gene may play a role in patients 
treated with IgG biologicals, such as IVIg and 
therapeutic monoclonal antibodies, by affecting 
their efficiency via IgG pharmacokinetics 
(PKs).8,9 But, how much do these alleles matter 
in autoimmune neurological therapeutics and 
whether the variable degrees of FcRn saturation, 
expression or inhibition are sufficient to influence 
the IgG catabolism dynamics and the circulating 
pathogenic autoantibodies or treatment efficacy, 
remain unsettled or under-recognized.
VNTR polymorphisms and their relation to 
efficacy of IVIg
A relation between VNTR polymorphisms and 
the outcome of IVIG therapy has been shown in 
common variable immunodeficiency (CVID), in 
which homozygous VNTR3/3 patients have higher 
FcRn expression resulting in higher protection by 
slowing the degradation of the administered IgG, 
compared to patients with the VNTR3/2 poly-
morphism.9,10 In contrast, in patients with auto-
immune or antibody-mediated autoimmune 
diseases the supraphysiological levels of IgG 
derived from IVIg administrations saturate the 
FcRn so the endogenously produced IgGs can be 
degraded rather than recycled and high serum lev-
els of infused IgG are ensured.11 Pharmacokinetic 
data from 174 patients with Guillain–Barré syn-
drome (GBS) have confirmed that 2 weeks after 
one IVIg administration the patients with a higher 
increase in circulating IgG had a significantly 
 better outcome.12 In a retrospective analysis, 
however, there was no relation between the 
VNTR3/3 polymorphism, the pharmacokinetics 
of IVIg, or the patients’ clinical course and out-
come.13 Although in this study the IgG data were 
limited and efficacy was assessed only up to 
2 weeks,13 similar results were also observed in 23 
patients with multifocal motor neuropathy,14 gen-
erating uncertainties as to the clinical significance 
of VNTR polymorphisms in IVIg therapeutics.
In this issue of the journal, Su et  al.6 explored 
whether VNTR3/3 and VNTR2/3 genotypes 
affected the efficacy of IVIg in 334 patients with 
myasthenia gravis (MG). They found that those 
with the VNTR2/3 genotype had significantly 
lower endogenous IgG levels and poor response 
to IVIg compared to patients with VNTR3/3 
homozygosity. Four VNTR2/3 patients who did 
not respond to IVIg, had a short duration of 
infused IVIg presumably due to fast IgG catabo-
lism that shortened IVIg retention and reduced 
its efficacy. It was concluded that in MG patients 
VNTR polymorphisms do matter and the VNTR2 
allele may be an indicator of lower IVIg efficacy. 
The results are interesting but challenging 
because the study did not assess if the VNTR 
polymorphisms influenced the catabolism of 
pathogenic AChR antibodies, or whether the 
VNTR3/2 alleles were less capable of protecting 
the infused IgG and affected the IgG pharma-
cokinetics resulting in IVIg ineffectiveness. In 
spite of these shortcomings, the paper is a stimu-
lus for new prospective studies to assess whether 
VNTR genotypes affect the levels and sustaina-
bility not only of the endogenous IgG but also of 
the infused IgG, and possibly answer the funda-
mental question as to why in all effective rand-
omized controlled studies in patients with Chronic 
Inflammatory Demyelinating Polyneuropathy 
(CIDP), GBS, multifocal motor neuropathy, MG, 
Dermatomyositis, or Stiff Person Syndrome,15–18 
20–30% of the patients did not respond to IVIg 
even if their disease status was identical to that of 
responders. IVIg has multiple functions via com-
plement, cytokines or idiotypic antibodies19 but 
whether the different VNTR genotypes also play a 
role will be of clinical importance even in retro-
spectively collected data. Because VTNR3/3 indi-
viduals protect and prolong the half-life of IgG 
more effectively than VTNR3/2 individuals, they 
may also protect pathogenic autoantibodies, gen-
erating complexities as to the specific role – if any 
– of VTNR polymorphisms in immunotherapies 
with IVIg or subcutaneous IgG. Such a 
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clarification is important because if among the 
20–30% of patients who do not respond to IVIg in 
controlled studies the ineffectiveness in some 
patients is due to VNTR genotypes that affect the 
half-life or the infused IgG levels, higher IVIg 
doses or more frequent administration will be 
needed. We have all seen patients infused with 3 g/
kg per month to achieve effectiveness, with a 
recent series of six CIDP patients responding only 
to super-high IVIg doses, up 4–6 g/kg per month.20
Effect of VNTR polymorphisms on efficacy of 
therapeutic monoclonal antibodies
Whether these polymorphisms have also an effect 
on therapeutic monoclonal antibodies (mAbs) has 
not been systematically explored. There is evi-
dence, however, that VNTR3 homozygous 
patients with normal circulating IgG levels have a 
lower mAb distribution clearance compared to 
VNTR2/VNTR3 and VNTR3/VNTR4 patients. 
The passage of cetuximab, a mAb against epider-
mal growth factor receptor, from the circulation to 
central compartments was shown to be slower in 
VNTR3 homozygous patients compared to hete-
rozygous patients, probably due to a higher expres-
sion of FcRn and higher recirculating capacity 
that retained cetuximab more efficiently in the cir-
culation.10 Similar results were observed with two 
anti-TNF-α agents, infliximab and adalimumab, 
in inflammatory bowel disease,21 and with farletu-
zumab, a mAb against α-folate receptor in ovarian 
cancer patients.22 The expression of FcRn in rele-
vance to VNTR polymorphisms may have there-
fore been an overlooked factor in understanding 
the PKs of therapeutic mAbs and explain their 
variable efficacy. It will also be of interest to exam-
ine whether efgartigimod as used in MG patients,23 
has a greater reduction in AChR antibody titers 
and better efficacy in VNTR3 homozygous 
patients, especially compared to IVIg.6
Role of FcRn in lowering serum IgG: current 
therapies with FcRn inhibitors
Lowering pathogenic IgG antibodies, either alone 
or in conjunction with other immune mediators, is 
a fundamental target in neurological therapeutics. 
This can now be achieved by: (a) Plasmapheresis, 
which non-specifically reduces the level not only 
of pathogenic antibodies (i.e. AChR in MG), but 
also of large plasma proteins including albumin, 
clotting factors or the IgG titers of various 
 protective antibodies;2 (b) Immunoadsorption, a 
therapeutic filtration procedure that removes spe-
cific physiological and pathological immunoglob-
ulins; (c) IVIg, which may potentially shorten the 
half-life of pathogenic autoantibodies by saturat-
ing the FcRn;2,11 and (d) FcRn inhibitors, a 
remarkable group of agents, very promising in 
neurotherapeutics of antibody-mediated diseases.
FcRn inhibitors bind FcRn with extremely high 
affinity at low and neutral pH enhancing catabo-
lism of all IgG subclasses leading to selective 
reduction of serum IgG (Figure 1B). Inhibition of 
FcRn reduces the circulation of both pathogenic 
and non-pathogenic IgG by up to 85% from base-
line in a dose-dependent manner,24,25 and at lev-
els as low as plasmapheresis does, but without 
affecting the turnover, production or quality of 
IgG autoantibodies. Of importance, FcRn inhibi-
tion does not affect other components of the 
innate or adaptive immune systems and does not 
exert a rebound effect on the total IgG levels.2,3 
The IgG reduction caused by FcRn inhibitors is, 
however, transient and reversible, returning to 
near-baseline levels 50–57 days after a single dose, 
and 50–80 days after multiple doses2 indicating 
that the function of memory B-cells and plasma 
cells remains unaffected.3 The immunogenicity of 
vaccines, especially important in this period of the 
COVID-19 pandemic, is not therefore compro-
mised by the FcRn inhibitors when vaccines are 
administered 4–8 weeks before treatment begins, 
allowing time for adaptive immunity to develop. 
Most importantly, based on present evidence, 
patients receiving a FcRn inhibitor have a limited 
risk of increased infection.2,3 The main FcRn 
inhibitors, currently in trials in neurology show-
ing promise especially in patients with MG in 
phase II–III studies, include:
(a) Efgartigimod (Argenx BVBA), a humanized 
IgG1 Fc fragment engineered to increase 
FcRn binding at neutral and acidic pH. A 
single dose reduces the total IgG level by 
50%, while repeated dosing lowers IgG by 
75%.23 The maximum IgG lowering effect is 
seen with 10 mg/kg which is the dose used in 
clinical studies. Early results in a placebo 
controlled, phase II study in 24 MG patients 
were impressive.23,26,27 Twelve patients 
received four doses over a 3-week period of 
10 mg/kg IV efgartigimod and 12 placebo. 
All the efgartigimod-receiving patients 
showed a rapid, within 2 weeks, decrease in 
the total IgG and anti-AChR autoantibody 
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levels; 75% of patients showed a rapid and 
long-lasting improvement in four efficacy 
scales coinciding with the maximal IgG low-
ering and reduction of AChR antibody lev-
els. The AChR antibody levels returned to 
normal within 8 weeks. Efgartigimod was not 
only effective but also safe and well tolerated 
leading to a phase III ADAPT study which 
solidified these results meeting the primary 
endpoint.27 In 167 generalized MG patients 
(129 AChR-Ab-positive and 38 AChR-Ab-
negative), efgartigimod showed clinically 
meaningful improvement in MG-ADL in 44 
of 65 (67.7%) AChR-positive patients com-
pared to 19 of 64 (29.7%) placebo-treated 
group (p < 0.0001) at 8 weeks. Slightly more 
than half of the efgartigimod-treated patients 
significantly improved 2 weeks after starting 
treatment. The results are remarkable espe-
cially considering that this novel therapeutic 
approach does not cause widespread immu-
nosuppression but a seemingly safe and 
meaningful reduction of endogenous IgG 
and AChR antibody levels.
(b) Rozanolixizumab is a high affinity human 
anti-FcRn IgG4 monoclonal antibody with 
marked decreases in plasma IgG concentra-
tions (75–90% from baseline) at 50 and 
150 mg/kg doses with maximal effects 
achieved by day 10. In a randomized but 
not robustly designed trial involving 43 MG 
patients, no statistically significant change 
from baseline in QMG, the study’s primary 
endpoint, was observed but, in spite of the 
negative results, the authors concluded that 
concluded that efficacy measures continued 
to improve leading to an ongoing phase III 
study (NCT03971422).28
(c) Nipocalimab is a human deglycosylated 
IgG1 anti-FcRn monoclonal antibody that 
binds with picomolar affinity to FcRn at both 
endosomal pH 6.0 and extracellular pH 7.6 
allowing occupancy of FcRn throughout the 
recycling pathway. Greater than 90% FcRn 
receptor occupancy was achieved with 3 mg/
kg doses within 2 h of dosing.3 Following one 
dose of 30 or 60 mg/kg, maximum IgG 
reductions of 74–80% were observed; 50% 
reductions in IgG levels were maintained for 
18–27 days for the 30–60 mg/kg dose, respec-
tively. During multiple doses, IgG levels 
were reduced by 85% below baseline by day 
14. The drug is currently undergoing a phase 
II trial in MG (NCT03772587).
FcRn inhibitors and IgG subclasses
Although the FcRn inhibitors lower all IgG sub-
classes, the IgG3 seems more affected compared 
to the other three subclasses.3 Any differential 
effect on reducing IgG subclasses can, however, 
be of great relevance to the treatment of IgG4-
related neurological diseases that do not respond 
to IVIg, such as 7% of MG patients with IgG4 
anti-MuSK antibodies26 and 10% of CIDP 
patients with nodal antibodies against neurofas-
cin-155, contacin or Caspr-1.29 Following the 
administration of both single and multiple doses 
of efgartigimod, reductions in IgG1-3 were 
equally reduced but with slightly smaller reduc-
tions for IgG4,30 suggesting perhaps less efficient 
FcRn blockade for IgG4. In contrast, studies of 
rozanolixizumab and orilanolimab reported dose-
dependent reductions in all four IgG subclasses, 
although most pronounced for IgG3.3,31 More 
information is therefore needed on their effective-
ness in IgG4-mediated autoimmunity, and 
whether they provide sustained benefits as good 
as seen with rituximab which is currently the pre-
ferred therapy.32
Significance of FcRn in the central nervous 
system
FcRn is highly expressed in the brain microvas-
cular endothelium and choroid plexus epithe-
lium. Because the endothelial cells of the brain 
capillaries are joined by tight junctions prevent-
ing the passive diffusion of signaling molecules, 
antibodies, and immune cells across the blood–
brain barrier (BBB), FcRn plays a key role in 
transporting IgG across the BBB preventing 
serum IgG from entering the Cerebrospinal Fluid 
(CSF)  and central nervous system (CNS) tissue. 
FcRn in the brain may, however, have a reverse 
role; instead of transporting IgG into the CNS, it 
may remove IgG from the CNS transporting it 
back to the circulation by reverse transcytosis 
across the BBB, protecting the brain by limiting 
CNS inflammation in pathological conditions 
such as bacteremia.1,2 On the other hand, when 
the BBB is disrupted by inflammatory mediators 
or injuries, such as during COVID-19 infection 
in comatose and stuporous patients,33 FcRn 
facilitates the entry of IgG antibodies from the 
circulation into the CNS.1,2 Accordingly, FcRn 
inhibitors may play a major role in treating CNS 
neuroinflammatory autoimmune diseases char-
acterized by impaired BBB integrity, as seen in 
SARS-CoV-2.
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